Skip to main content

Month: March 2020

BWMG’s BLU3 Submits Manufacturing Proposals to Utilize Existing BLU3 Product in Response to Increasing Global Demand for Ventilators Due to COVID-19

Pompano Beach, Florida, March 23, 2020 (GLOBE NEWSWIRE) — Brownie’s Marine Group, Inc. (OTC:BWMG) a leading developer, manufacturer and distributor of modern recreational diving products and onboard compressed air solutions is pleased to announce that, through its wholly owned subsidiary, BLU3, Inc., it has submitted a technical proposal in response to the Department of Defense DIY Hack-A-Vent Innovation Challenge and other similar initiatives seeking innovative ways to rapidly produce ventilators during this time of critical demand due to COVID-19.About Hack-a-VentAccording to DOD’s Vulcan, “this Innovation Challenge seeks to pool brilliant minds and expertise to develop a low-cost, non-FDA approved, mechanical ventilation support system that can be rapidly produced at local levels with widely available resources. The top 3 submissions...

Continue reading

New York Mortgage Trust Provides Update on Status of Financing Arrangements as of March 23, 2020

NEW YORK, March 23, 2020 (GLOBE NEWSWIRE) — New York Mortgage Trust, Inc. (Nasdaq: NYMT) (the “Company”) announced today that due to the turmoil in the financial markets resulting from the global pandemic of the COVID-19 virus, the Company and its subsidiaries (the “Company”) have received margin calls from repurchase agreement financing counterparties over the past week. Through Friday March 20, 2020, the Company timely met all margin calls received.  However, due to the continued margin calls received for March 23, 2020, the Company has notified its financing counterparties that it does not expect to fund the existing and anticipated future margin calls under its financing arrangements in the near term.The Company is engaging in discussions with its financing counterparties with regard to entering into a forbearance agreement...

Continue reading

Apergy Provides Business Update

Implementing immediate downturn contingency plans expected to result in approximately $65 million of annual cost savings to preserve margins and cash flowCapital expenditures in 2020 to be reduced by approximately 65% from 2019Available liquidity of over $270 millionContinuing to monitor market developments and prepared to take additional actions as necessaryTHE WOODLANDS, Texas, March 23, 2020 (GLOBE NEWSWIRE) — Apergy Corporation (“Apergy” or “the Company”) (NYSE: APY) today announced a set of immediate actions that the Company is taking in response to the significant decline in oil prices due to the outcome of OPEC+ meeting in early March 2020, as well as market volatility arising from the COVID-19 pandemic.The Company’s announced actions immediately reduce operating costs and capital spending to align to the expected decline...

Continue reading

CytomX Therapeutics and Astellas Announce Strategic Collaboration to Develop Probody® T-Cell Engaging Bispecific Therapies for Treatment of Cancer

      – Collaboration to Utilize CytomX’s Novel Probody® Technology Platform for CD3 Bispecific Targets –      – CytomX to Receive $80 Million Upfront Payment and      Ability to Exercise Option for U.S. Co-Commercialization Rights –SOUTH SAN FRANCISCO, Calif. and TOKYO, March 23, 2020 (GLOBE NEWSWIRE) — CytomX Therapeutics, Inc. (NASDAQ: CTMX, President, Chief Executive Officer and Chairman: Sean McCarthy, D. Phil. “CytomX”) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today announced they have entered into a strategic collaboration agreement focused on the discovery, research, development and commercialization of novel T-cell engaging bispecific antibodies targeting CD3 and tumor cell surface antigens for the treatment of cancer.  The parties will utilize CytomX’s...

Continue reading

GenMark Awarded BARDA Grant for the Development of ePlex® RP2 Panel

CARLSBAD, Calif., March 23, 2020 (GLOBE NEWSWIRE) — GenMark Diagnostics, Inc. (NASDAQ:GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced it has been awarded a grant from the Biomedical Advanced Research and Development Authority (BARDA), part of the Department of Health and Human Services (HHS) Office of the Assistant Secretary for Preparedness and Response (ASPR).In working with public and private partners to find solutions to mitigate the impact of COVID-19, BARDA will provide GenMark with up to $749,000 in funding to develop and pursue U.S. Food and Drug Administration (FDA) Emergency Use Authorization (EUA) of a diagnostic panel that incorporates the new SARS-CoV-2 viral target into the company’s existing ePlex Respiratory Pathogen (RP) panel. With this additional support...

Continue reading

LEONOVUS INC. ANNOUNCES 2019 FINANCIAL RESULTS

OTTAWA, March 23, 2020 (GLOBE NEWSWIRE) — Leonovus Inc., (“Leonovus”) (TSXV: LTV) today announced its operating and financial results for the year ended December 31, 2019. Amounts are in U.S. dollars unless otherwise stated.The Company recorded revenues of $24,000 in 2019 compared to revenues of $14,000 in 2018. The Company was awarded a contract in the amount of $435,700 with the Government of Canada Business in Canada Innovation Program. Revenues from this contract will begin in Q1 2020 and run through to Q1 2021.The Company incurred a net loss of $5,193,000 in the year ended 2019 compared to a net loss of $4,924,000 in 2018. Total operating expenses decreased to $4,532,000 for the year 2019 compared to $5,077,000 in 2018. The Company had cash and short-term investments of $583,000 as of December 31, 2019, as compared to $3,646,000...

Continue reading

UPDATE: CapStar Announces Proactive Initiatives to Support Its Employees, Clients, and Communities in Response to COVID-19

NASHVILLE, March 23, 2020 (GLOBE NEWSWIRE) — CapStar Bank, a subsidiary of CapStar Financial Holdings (NASDAQ: CSTR), has launched several initiatives and proactive response plans to protect the health of and provide economic relief for its employees, clients, and communities due to the COVID-19 virus outbreak.“During this unprecedented time, CapStar is doing everything we can to serve as a source of strength for our employees, clients, and communities,” said Timothy K. Schools, CapStar President & Chief Executive Officer. “As a result, we have adjusted our operations to protect the health and well-being of our employees, their families, and our clients while remaining true to our mission of superior service; are proactively offering 90-day full deferment of qualifying loan payments to CapStar borrowers that are less...

Continue reading

CORE GOLD TEMPORARILY SUSPENDS OPERATIONS AT DYNASTY GOLDFIELD

VANCOUVER, British Columbia, March 23, 2020 (GLOBE NEWSWIRE) — Core Gold Inc. (“Core Gold” or the “Company“) (TSX-V: CGLD, OTCQX: CGLDF), is announced that the Company is temporarily suspending operations at its Dynasty Goldfield project in Ecuador amid growing concerns regarding the spread of the coronavirus (COVID-19) in the country. Central, Provincial and local Municipality government decrees regarding gatherings, travel and transport within Ecuador will impact the Company’s ability to efficiently operate and therefore the Company has elected to suspend operations during this difficult time.Core Gold will maintain a workforce at Dynasty Goldfield to conduct care and maintenance activities and special projects in order to minimize the impacts of this temporary shutdown. In the upcoming weeks, the Core...

Continue reading

Marathon Patent Group Announces 2019 Fiscal Year End Financial Results

LAS VEGAS, March 23, 2020 (GLOBE NEWSWIRE) — Marathon Patent Group, Inc. (NASDAQ:MARA) (“Marathon” or “Company”), today announced its operating results for the twelve months ended December 31, 2019, as published in its Annual Report on Form 10-K filed today with the Securities and Exchange Commission.Operating Results for the Year Ended December 31, 2019Total revenue was $1.2 million for the year ended December 31, 2019 compared to $1.6 million for the year ended December 31, 2018.Operating loss improved to approximately $4.2 million (inclusive of non-cash expenses) for the year ended December 31, 2019 compared to an operating loss of approximately $12.1 million (inclusive of non-cash expenses) for the year ended December 31, 2018.GAAP net loss improved to $(0.53) per basic and diluted share for the year ended...

Continue reading

Eyenovia, Inc. Announces Approximately $6.0 Million Private Placement

NEW YORK, March 23, 2020 (GLOBE NEWSWIRE) — Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose therapeutics utilizing its patented piezo-print technology, today announced that it has received subscriptions for a private placement in the amount of approximately $6.0 million of units at a price to the public of $2.21425 per unit. The offering is expected to close on or about March 24, 2020, subject to customary closing conditions.Each unit consists of (i) one share of common stock, par value $0.0001 per share, (ii) a one-year warrant to purchase 0.5 of a share of common stock, and (iii) a five-year warrant to purchase 0.75 of a share of common stock.The proceeds of the offering are expected to be used, together with other available funds, for the MicroLine and MicroPine...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.